<DOC>
	<DOCNO>NCT02102022</DOCNO>
	<brief_summary>Assessment safety tolerability ADI-PEG 20 combination folinic acid ( leucovorin ) , fluorouracil oxaliplatin ( FOLFOX ) advance GI malignancy .</brief_summary>
	<brief_title>Ph 1 Study ADI-PEG 20 Plus FOLFOX Subjects With Advanced Gastrointestinal Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>For Advanced GI Malignancies ( Dose Escalation MTD Cohorts ) : 1 . Advanced histologically proven GI cancer . 2 . First line progressive disease already treat form therapy , include limited chemotherapy , radiotherapy , local therapy , surgery immunotherapy . Patients HCC fail sorafenib , document PD AEs result discontinuance agent . Patients pancreatic cancer ( dose escalation ) progress follow gemcitabine base regimen . Subjects fail prior platinum contain regimen eligible . Gastric cancer subject express tumor HER2 amplification must treat trastuzumab prior enrollment , unless trastuzumab available indication particular country . 3 . Measurable disease use RECIST 1.1 criterion ( Appendix A ) . At least 1 measurable lesion must present . Subjects receive localregional therapy ( limited ) chemoembolization , embolization , cryoablation , hepatic artery therapy , percutaneous ethanol injection , radiation therapy , radiofrequency ablation surgery eligible , provide either target lesion treated local therapy and/or target lesion ( ) within field local regional therapy show increase ≥ 20 % size . Localregional therapy must complete least 4 week prior baseline CT scan . 4 . ECOG performance status 0 1 . 5 . Expected survival least 3 month . For HCC ( Dose Escalation MTD Expansion ) : 19 . Prior treatment sorafenib , document PD AEs result discontinuance agent . Patient may treat line therapy well exclude ADIPEG 20 . 20 . Cirrhotic status ChildPugh grade A. ChildPugh status determine base clinical finding laboratory data screen period ( Appendix C ) . Subjects Coumadin anticoagulant receive 1 point INR status . 21 . Serum albumin level ≥ 2.8 g/dl . 22 . Prothrombin time ( PT ) international normalize ratio ( INR ) : PT &lt; 6 second control INR &lt; 1.7 . Subjects Coumadin anticoagulant receive 1 point INR status . 23 . Subjects active hepatitis B C antiviremic compound may remain treatment , except interferon . 1 . Serious infection require treatment systemically administer antibiotic time study entrance , infection require systemic antibiotic therapy within 7 day prior first dose study treatment . 2 . Pregnancy lactation . 3 . Expected noncompliance . 4 . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure ( New York Heart Association Class III IV ) , cardiac arrhythmia , psychiatric illness , social situation would limit compliance study requirement . 5 . Subjects anticancer treatment prior enter study recover baseline ( except alopecia ) ≤ Grade 1 AEs , deem irreversible effect prior cancer therapy . AEs &gt; Grade 1 consider safety risk Sponsor investigator may allow upon agreement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>argininosuccinate synthetase</keyword>
	<keyword>arginine</keyword>
	<keyword>arginine deiminase</keyword>
</DOC>